Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
- Written by Newsfile
Promising Results Merit Larger Study Which Awakn is Initiating
Toronto, Ontario--(Newsfile Corp. - May 19, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD),...